{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 0.4366836, "regularMarketPrice": 0.299, "exchange": "NCM", "shortName": "Landos Biopharma, Inc.", "longName": "Landos Biopharma, Inc.", "messageBoardId": "finmb_432438570", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 0.972, "fiftyDayAverage": 0.28756, "fiftyDayAverageChange": 0.011440009, "fiftyDayAverageChangePercent": 0.039783034, "twoHundredDayAverage": 0.480595, "twoHundredDayAverageChange": -0.181595, "twoHundredDayAverageChangePercent": -0.37785453, "marketCap": 9360075, "forwardPE": -0.934375, "priceToBook": 0.30761316, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-04", "averageAnalystRating": "3.7 - Underperform", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1683892801, "earningsTimestampStart": 1691584200, "earningsTimestampEnd": 1692016200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.98, "epsForward": -0.32, "epsCurrentYear": -0.44, "priceEpsCurrentYear": -0.67954546, "sharesOutstanding": 31168400, "firstTradeDateMilliseconds": 1612449000000, "priceHint": 4, "regularMarketChange": 0.0013000071, "regularMarketTime": 1684180346, "regularMarketDayHigh": 0.3079, "regularMarketDayRange": "0.274901 - 0.3079", "regularMarketDayLow": 0.274901, "regularMarketVolume": 24847, "regularMarketPreviousClose": 0.2977, "bid": 0.0, "ask": 0.0, "bidSize": 18, "askSize": 29, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.2888, "averageDailyVolume3Month": 194881, "averageDailyVolume10Day": 47160, "fiftyTwoWeekLowChange": 0.088, "fiftyTwoWeekLowChangePercent": 0.41706163, "fiftyTwoWeekRange": "0.211 - 1.37", "fiftyTwoWeekHighChange": -1.071, "fiftyTwoWeekHighChangePercent": -0.7817518, "fiftyTwoWeekLow": 0.211, "fiftyTwoWeekHigh": 1.37, "marketState": "PRE", "displayName": "Landos Biopharma", "symbol": "LABP"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1800 Kraft Drive", "address2": "Suite 216", "city": "Blacksburg", "state": "VA", "zip": "24060", "country": "United States", "phone": "540 218 1767", "website": "https://landosbiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gregory  Oakes", "age": 54, "title": "Pres, CEO & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 1035787, "fmt": "1.04M", "longFmt": "1,035,787"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy M. Mayleben M.B.A.", "age": 61, "title": "Principal Financial Officer & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 555993, "fmt": "555.99k", "longFmt": "555,993"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Patrick  Truesdell", "age": 40, "title": "VP , Controller & Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": {"raw": 368835, "fmt": "368.83k", "longFmt": "368,835"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Fabio  Cataldi M.D.", "title": "Exec. VP & Chief Medical Officer", "fiscalYear": 2022, "totalPay": {"raw": 516679, "fmt": "516.68k", "longFmt": "516,679"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rebecca  Mosig Ph.D.", "title": "Exec. Director of Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Josep  Bassaganya-Riera DVM, Ph.D.", "age": 47, "title": "Advisor", "yearBorn": 1975, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}